# A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Source: https://onco.cc/trials/nct05428969/  
OnCo record `nct05428969` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Azacitidine and Venetoclax in acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and myelodysplastic syndromes / neoplasms, run by Faron Pharmaceuticals Ltd, active and no longer recruiting.

## Summary

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies is a phase 1/2 interventional study registered as NCT05428969 by Faron Pharmaceuticals Ltd, with 181 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2027-03. Interventions recorded: Bexmarilimab, Azacitidine and Venetoclax.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05428969
- Phase: 1/2
- Setting: A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
- Sponsor: Faron Pharmaceuticals Ltd
- Enrolled: 181

## Sources

- ClinicalTrials.gov NCT05428969: https://clinicaltrials.gov/study/NCT05428969

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Bexmarilimab](https://onco.cc/drugs/bexmarilimab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)

---
JSON: https://onco.cc/api/v1/entities/nct05428969.json